Agilent Technologies (Agilent Technologies) Risk Assessment

View and export this data going back to 1999. Start your Free Trial

What is Agilent Technologies Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Agilent Technologies is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of Agilent Technologies's Risk Assessment

For the Diagnostics & Research subindustry, Agilent Technologies's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agilent Technologies's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Agilent Technologies's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Agilent Technologies's Risk Assessment falls into.

Agilent Technologies (NYSE:A) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Agilent Technologies Risk Assessment Related Terms

Thank you for viewing the detailed overview of Agilent Technologies's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Agilent Technologies (Agilent Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Agilent Technologies Inc (NYSE:A) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

A:Mexico 1A:Italy AG8:Germany AG8:Germany

Address

5301 Stevens Creek Boulevard, Santa Clara, CA, USA, 95051

Website

https://www.agilent.com

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab (consisting of consumables and services related to life science and applied tools), and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. and China representing the largest country concentrations.

Executives

Philip Binns	officer: Senior Vice President	5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Rodney Gonsalves	officer: V.P., Corporate Controller	5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Henrik Ancher-jensen	officer: Sr. Vice President	5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Michael R. Mcmullen	officer: CEO and President	5301 STEVENS CREEK BLVD., MS 1A-LC, SANTA CLARA CA 95051
George A Scangos	director	C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083
Otis W Brawley	director	5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Mikael Dolsten	director	5 GIRALDA FARMS, MADISON NJ 07940
Mala Anand	director	C/O COTIVITI HOLDINGS, INC., 115 PERIMETER CENTER PLACE, SUITE 700, ATLANTA GA 30346
Sue H. Rataj	director	C/O CABOT CORPORATION, TWO SEAPORT LANE, SUITE 1300, BOSTON MA 02210
Dow R Wilson	director	VARIAN MEDICAL SYSTEMS INC, 3100 HANSEN WAY MAIL STOP E327, PALO ALTO CA 94304
Boon Hwee Koh	director	C/O AGILENT TECHNOLOGIES, 5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Heidi Fields	director	5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Hans Edgar Bishop	director	60 WEST 66TH STREET, 26A, NEW YORK NY 10023
Daniel K Podolsky	director	5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Padraig Mcdonnell	officer: Senior Vice President	5301 STEVENS CREEK BLVD, SANTA CLARA CA 95051